A multicenter phase III study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies

News archive

 

• 
  Jan New Publication "PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial"
  → more
  January 2019


• 
  Jan Clinical development of PLX-PAD in Critical Limb Ischemia- CLI design paper (Pluristem)
  → more
  January 2019


• 
  
  Jun Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study.
  ● More on Press releases
  June, 2018


• 
  FebBe sure to read Prof Dr. Sigrid Nikol’s (Asklepios PI) interview on LINK today and Jerusalem Posts
  February, 2018


• 
  JulPACE website online
  july, 2017